GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Cyclically Adjusted PB Ratio

Dare Bioscience (Dare Bioscience) Cyclically Adjusted PB Ratio : 0.06 (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Dare Bioscience's current share price is $0.41. Dare Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $6.75. Dare Bioscience's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Dare Bioscience's Cyclically Adjusted PB Ratio or its related term are showing as below:

DARE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.15   Max: 0.39
Current: 0.06

During the past years, Dare Bioscience's highest Cyclically Adjusted PB Ratio was 0.39. The lowest was 0.04. And the median was 0.15.

DARE's Cyclically Adjusted PB Ratio is ranked better than
90.85% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs DARE: 0.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Dare Bioscience's adjusted book value per share data for the three months ended in Mar. 2024 was $-0.109. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dare Bioscience Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Dare Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Cyclically Adjusted PB Ratio Chart

Dare Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.24 0.06

Dare Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.27 0.14 0.06 0.07

Competitive Comparison of Dare Bioscience's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Dare Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dare Bioscience's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's Cyclically Adjusted PB Ratio falls into.



Dare Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Dare Bioscience's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.41/6.75
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dare Bioscience's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.109/131.7762*131.7762
=-0.109

Current CPI (Mar. 2024) = 131.7762.

Dare Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201406 28.727 100.560 37.645
201409 26.103 100.428 34.251
201412 22.522 99.070 29.957
201503 19.646 99.621 25.987
201506 24.982 100.684 32.697
201509 21.444 100.392 28.148
201512 17.824 99.792 23.537
201603 13.150 100.470 17.247
201606 9.443 101.688 12.237
201609 6.069 101.861 7.851
201612 -0.246 101.863 -0.318
201703 2.667 102.862 3.417
201706 1.398 103.349 1.783
201709 3.709 104.136 4.693
201712 2.198 104.011 2.785
201803 1.385 105.290 1.733
201806 1.070 106.317 1.326
201809 0.839 106.507 1.038
201812 0.589 105.998 0.732
201903 0.331 107.251 0.407
201906 0.305 108.070 0.372
201909 0.108 108.329 0.131
201912 0.022 108.420 0.027
202003 0.130 108.902 0.157
202006 0.011 108.767 0.013
202009 -0.041 109.815 -0.049
202012 -0.028 109.897 -0.034
202103 0.069 111.754 0.081
202106 0.135 114.631 0.155
202109 0.416 115.734 0.474
202112 0.462 117.630 0.518
202203 0.368 121.301 0.400
202206 0.389 125.017 0.410
202209 0.311 125.227 0.327
202212 0.131 125.222 0.138
202303 0.058 127.348 0.060
202306 -0.031 128.729 -0.032
202309 -0.023 129.860 -0.023
202312 -0.050 129.419 -0.051
202403 -0.109 131.776 -0.109

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dare Bioscience  (NAS:DARE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Dare Bioscience Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dare Bioscience (Dare Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Executives
Sophia Nnenna Ononye-onyia director 1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson director, officer: Chef Executive Officer 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair officer: Chief Strategy Officer C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley director 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz director 1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman director C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert officer: Chief Financial Officer C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof officer: SVP, Chief Scientific Officer C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz officer: SVP, Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle director VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal officer: VP, General Counsel C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill officer: Principal Accounting Officer 15 GREENBRIAR CIRCLE, ANDOVER MA 01810

Dare Bioscience (Dare Bioscience) Headlines

From GuruFocus